We are live on ! Find out more
MDCO

Medicines Co
MDCO

Delisted

MDCO was delisted on the 3rd of January, 2020.

228 hedge funds and large institutions have $3.76B invested in Medicines Co in 2019 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 91 increasing their positions, 57 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

108% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 25

60% more repeat investments, than reductions

Existing positions increased: 91 | Existing positions reduced: 57

34% more capital invested

Capital invested by funds: $2.8B → $3.76B (+$958M)

33% more funds holding in top 10

Funds holding in top 10: 68 (+2)

12% more funds holding

Funds holding: 203228 (+25)

30% less call options, than puts

Call options by funds: $224M | Put options by funds: $320M

Holders
228
Holders Change
+25
Holders Change %
+12.32%
% of All Funds
4.95%
Holding in Top 10
8
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+33.33%
% of All Funds
0.17%
New
52
Increased
91
Reduced
57
Closed
25
Calls
$224M
Puts
$320M
Net Calls
-$95.3M
Net Calls Change
-$70.2M
Name Holding Trade Value Shares
Change
Change in
Stake
TCM
51
Tekla Capital Management
Massachusetts
$10.1M -$499K -15,300 -5%
UONDDL
52
University of Notre Dame du Lac
Indiana
$9.84M +$5.29M +162,168 +151%
AA
53
Antipodean Advisors
New York
$9.37M +$2.84M +87,000 +51%
FCMI
54
Foresite Capital Management IV
California
$9.11M +$8.15M +249,672 New
Wells Fargo
55
Wells Fargo
California
$9.03M +$5.97M +182,964 +284%
Two Sigma Investments
56
Two Sigma Investments
New York
$8.82M +$7.56M +231,700 +2,276%
UBS Group
57
UBS Group
Switzerland
$8.1M -$9.32M -285,428 -56%
RhumbLine Advisers
58
RhumbLine Advisers
Massachusetts
$8.08M +$844K +25,855 +13%
CS
59
Candriam SCA
Luxembourg
$8.04M +$2.77M +85,000 +62%
AI
60
Atom Investors
Texas
$7.96M +$5.75M +176,251 +421%
PPA
61
Parametric Portfolio Associates
Washington
$7.92M +$287K +8,795 +4%
6CM
62
683 Capital Management
New York
$7.84M +$1.56M +47,748 +29%
RPAM
63
Rhenman & Partners Asset Management
Sweden
$7.29M +$2.29M +70,000 +54%
AIMCA
64
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$6.71M -$1.31M -40,200 -18%
Legal & General Group
65
Legal & General Group
United Kingdom
$6.66M +$271K +8,294 +5%
Public Sector Pension Investment Board (PSP Investments)
66
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$5.61M +$3.05M +93,300 +154%
O
67
OrbiMed
New York
$5.53M +$4.95M +151,515 New
MIM
68
Monashee Investment Management
Massachusetts
$5.47M +$4.9M +150,000 New
New York State Teachers Retirement System (NYSTRS)
69
New York State Teachers Retirement System (NYSTRS)
New York
$5.35M
SCM
70
Sterling Capital Management
North Carolina
$5.33M -$330K -10,114 -6%
Citigroup
71
Citigroup
New York
$5.19M +$4.54M +139,092 +4,268%
Rafferty Asset Management
72
Rafferty Asset Management
New York
$5.18M +$4.63M +141,979 New
Barclays
73
Barclays
United Kingdom
$5.01M +$2.99M +91,702 +200%
Swiss National Bank
74
Swiss National Bank
Switzerland
$5.01M +$88.1K +2,700 +2%
CFM
75
Coronation Fund Managers
South Africa
$4.81M -$662K -20,290 -13%

MDCO Hedge Fund Activity: Q2 2019 in Review

228 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Medicines Co (MDCO) for Q2 2019, worth a combined $3.76B — up 34% from $2.8B a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new MDCO positions and 25 closed out — a net gain of 27 holders — while 91 added to existing stakes and 57 trimmed.

The largest buyer was State Street, adding an estimated $46.7M. The largest seller was Aviva Holdings, cutting an estimated $91.3M.

  • 228 institutional investors held Medicines Co (MDCO) as of Q2 2019, up from 203 in Q1 2019.
  • Funds reported $3.76B of Medicines Co stock for Q2 2019, up 34% quarter-over-quarter.
  • 52 funds opened new Medicines Co positions in Q2 2019 and 25 closed out, a net change of +27 holders.
  • The largest Medicines Co buyer in Q2 2019 was State Street, an estimated $46.7M added.
  • The largest Medicines Co seller in Q2 2019 was Aviva Holdings, an estimated $91.3M sold.

Based on aggregated 13F filings for Q2 2019.